Tenecteplase a viable alternative to alteplase in acute ischaemic stroke

1 giờ trước
Tenecteplase a viable alternative to alteplase in acute ischaemic stroke

Stroke severity and mechanical thrombectomy, rather than the choice of thrombolytic agent, are significantly associated with adverse outcomes in patients with acute ischaemic stroke (AIS), as shown in a recent study.

A total of 832 patients with AIS treated with alteplase or tenecteplase were included in this retrospective, real-world, multicentre chart review. The incidence of symptomatic intracranial haemorrhage (sICH) was the primary outcome, while major bleeding and all-cause in-hospital mortality were secondary outcomes.

Patients treated with alteplase and those prescribed tenecteplase showed no statistically significant differences in sICH (8.8 percent vs 7.3 percent; p=0.5), major bleeding (10.9 percent vs 10.5 percent; p=0.9), or in-hospital mortality (5.1 percent vs 5.5 percent; p=0.9).

Notably, higher National Institutes of Health Stroke Scale scores and mechanical thrombectomy significantly correlated with an elevated risk of bleeding and mortality, regardless of the thrombolytic agent used.

Moreover, the safety profile of tenecteplase was also similar to that of alteplase in the treatment of AIS, with no significant differences in sICH, major bleeding, or in-hospital mortality.

“These findings support tenecteplase as an alternative to alteplase for AIS thrombolysis,” according to the investigators.

“Alteplase has long been the standard thrombolytic therapy for AIS, [but] tenecteplase has recently gained attention due to its favourable pharmacokinetics and simplified administration,” they added.

J Pharm Pract 2026;39:495-501